GLP-1 Receptor Agonists in Heart Failure

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Heart failure (HF) presents a significant public health challenge, exacerbated by rising rates of obesity and diabetes.
• Despite advancements, HF remains linked to substantial morbidity and mortality.
• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2 diabetes, exhibit cardiovascular benefits.

Purpose of the Study:

• To explore the mechanistic overlap between GLP-1 receptor signaling and heart failure pathophysiology.
• To evaluate the potential of GLP-1 RAs as adjunctive therapies for heart failure, particularly in metabolically driven forms.

Main Methods:

• Review of recent clinical trials (e.g., STEP-HFpEF, SUMMIT) demonstrating GLP-1 RA efficacy in HFpEF.
• Analysis of biological pathways influenced by GLP-1 RAs relevant to HF.
• Examination of GLP-1 RA effects on sympathetic activity, inflammation, oxidative stress, and cardiac metabolism.

Main Results:

• GLP-1 RAs have shown improvements in HFpEF symptoms and significant weight loss.
• These agents modulate pathways including sympathetic nervous system activity, inflammatory cytokine signaling, and oxidative stress.
• GLP-1 RAs impact vascular function, endothelial health, and renal sodium handling, improving hemodynamics.

Conclusions:

• GLP-1 RAs demonstrate a mechanistic link to HF pathophysiology through systemic metabolic and anti-inflammatory actions.
• Observed clinical benefits in HF patients are supported by these multifaceted biological effects.
• GLP-1 RAs represent a potential adjunctive treatment strategy for specific HF phenotypes, warranting further investigation into direct cardiac effects.